Primary malignant hepatic pheochromocytoma with negative adrenal scintigraphy

Hypertens Res. 2006 Jul;29(7):551-4. doi: 10.1291/hypres.29.551.

Abstract

A 60-year-old male patient with hypertension was referred to our hospital because of insufficient blood pressure control (190/98 mmHg) and to rule out secondary hypertension. A computed tomography scan revealed no adrenal tumor but a large liver mass (5 x 5 cm), and magnetic resonance imaging showed a high signal intensity lesion on the T2-weighted image. Twenty-four hour urinary excretion of catecholamine metabolites was markedly increased, although a 123I-metaiodobenzyl guanidine (MIBG) scintigram failed to show accumulation in the hepatic mass, and no difference was noted between the catecholamine concentration in the tumor-drainage vein and that obtained from the vein draining from the non-tumor area. Liver biopsy did show features compatible with pheochromocytoma (i.e., chromogranin A-positive cells). Transcatheter arterial embolization of the liver tumor was conducted and resulted in a marked (50%) decrease in the 24-h urine normetanephrine excretion. Several metastatic foci were noted in the spinal bone and transcatheter arterial embolization (TAE) was also conducted with successful results. Thus, we experienced a case of primary malignant hepatic pheochromocytoma with negative 123I-MIBG scanning.

Publication types

  • Case Reports

MeSH terms

  • 3-Iodobenzylguanidine
  • Adrenal Glands / diagnostic imaging*
  • Biopsy
  • Catecholamines / urine
  • Humans
  • Hypertension / etiology
  • Liver / diagnostic imaging
  • Liver / pathology
  • Liver Neoplasms / complications
  • Liver Neoplasms / diagnostic imaging*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Pheochromocytoma / complications
  • Pheochromocytoma / diagnostic imaging*
  • Radionuclide Imaging
  • Radiopharmaceuticals

Substances

  • Catecholamines
  • Radiopharmaceuticals
  • 3-Iodobenzylguanidine